GlassScriptPhysician profile
Michelle Akella
NPI 1023643970
$5,289.34
in general payments reported to CMS, 2019-2025
28 companies · $1,925 in 2025
The $1,925 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $869 · 2022: $1,111 · 2023: $819 · 2024: $566 · 2025: $1,925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,765 · Travel and Lodging: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.09 |
| Travel and Lodging | $544.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $791.93 | 2021-2024 | Xarelto |
| Cvrx, INC. | $762.35 | 2022-2025 | Barostim Neo System |
| Pfizer INC. | $658.54 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.53 | 2021-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $374.21 | 2022-2025 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $373.86 | 2021-2025 | Camzyos, Eliquis |
| Biotronik INC. | $356.98 | 2025 | Acticor 7 Vr-T Dx, Amvia Edge, Rivacor 7 Dr-T |
| Novartis Pharmaceuticals Corporation | $317.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $180.76 | 2021-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $165.14 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $102.53 | 2021-2023 | Verquvo |
| Biosense Webster, INC. | $95.69 | 2022-2025 | Na |
| Medtronic, INC. | $91.95 | 2021-2023 | Reveal Linq, Micra |
| Amgen INC. | $87.75 | 2023-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.64 | 2023-2025 | Lifevest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $80.14 | 2024-2025 | Watchman Flx, General - Therapies |
| Jubilant Draximage, INC. | $67.22 | 2025 | Technetium Tc 99m Sestamibi |
| Esperion Therapeutics, INC. | $62.98 | 2021 | |
| Inari Medical, INC. | $35.81 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Glaxosmithkline, LLC. | $34.14 | 2025 | Arexvy, Shingrix |
| Kestra Medical Technology Services, INC. | $32.41 | 2022 | |
| Elutia, INC. | $29.41 | 2025 | Ecm Patch,Pouch |
| Astellas Pharma US INC | $27.14 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $26.40 | 2023 | Optimizer |
| Cardiva Medical, INC. | $20.78 | 2024 | Cardiva Vascade 6/7f Vcs |
| Acutus Medical, INC. | $18.97 | 2023 | |
| Lundbeck LLC | $18.80 | 2021 | |
| G Medical Diagnostic Services, INC. | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Akella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.